Latest news with #GuardantInfinity™
Yahoo
27-05-2025
- Business
- Yahoo
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
For the first time, fundamental tumor phenotypes determined by a simple blood test Single test now provides molecular tumor typing, subtyping and confirmation of absence of actionable biomarkers to give clinicians critical insights to guide optimal treatment PALO ALTO, Calif., May 27, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360® Liquid test that greatly expand its biomarker identification and cancer subtyping capabilities to help oncologists identify optimal treatment plans. The expanded applications are enabled through the multiomic profiling capabilities of the Guardant Infinity™ smart liquid biopsy platform and its AI learning engine, which analyzes large sets of patient data to identify patterns and refine predictions. Some of the groundbreaking new applications for the Guardant360 Liquid test will allow healthcare providers to do the following in order to improve patient outcomes: Confirm no actionable mutations in lung and colorectal cancers—helping fast-track patients to treatment without extra testing. Identify the origin of cancers when the primary site is unknown, guiding better diagnosis and therapy. Classify breast ER/PR/HER2 status and lung cancer histology subtypes with high precision by interpreting tumor-specific methylation signatures, enhancing standard testing methods. Use pharmacogenomics to identify genetic variations vital for safe and effective use of common anti-cancer therapies, including those with FDA black box labeling. Detect human papillomavirus (HPV) and Epstein-Barr (EBV), which influence prognosis and treatment plans in certain cancers. Determine Homologous Recombination Deficiency (HRD) status to inform use of specific therapies like PARP inhibitors and platinum-based chemotherapy. Use Human Leukocyte Antigen (HLA) genotyping as a biomarker to inform therapy selection and identify clinical trial opportunities. "For the first time ever, we're able to reveal vital details about a tumor – including its fundamental phenotype and biological behavior – from just a blood sample," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "This gives healthcare providers the insights they need about a patient's cancer to make smarter treatment decisions, even when they can't access tumor tissue for analysis. The novel blood-based approach to comprehensive molecular profiling using our Guardant Infinity Smart Liquid Biopsy platform offers immense potential for future applications in cancer and beyond." Comprehensive biomarker testing through immunohistochemistry using tumor tissue has been the standard of care in oncology and helps ensure that clinicians don't miss critical information about a patient's specific type of cancer. The Guardant360 Liquid test now provides access to this extensive molecular profiling information through the blood by looking at the unique methylation signatures of specific tumor biomarkers. Guardant liquid biopsy tests have been clinically validated in more than 1,000 publications and research abstracts. Test results for Guardant360 Liquid are available within seven days. For more information, visit the Guardant Health website. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Michael Weistpress@ +1 317-371-0035
Yahoo
27-05-2025
- Business
- Yahoo
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
For the first time, fundamental tumor phenotypes determined by a simple blood test Single test now provides molecular tumor typing, subtyping and confirmation of absence of actionable biomarkers to give clinicians critical insights to guide optimal treatment PALO ALTO, Calif., May 27, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360® Liquid test that greatly expand its biomarker identification and cancer subtyping capabilities to help oncologists identify optimal treatment plans. The expanded applications are enabled through the multiomic profiling capabilities of the Guardant Infinity™ smart liquid biopsy platform and its AI learning engine, which analyzes large sets of patient data to identify patterns and refine predictions. Some of the groundbreaking new applications for the Guardant360 Liquid test will allow healthcare providers to do the following in order to improve patient outcomes: Confirm no actionable mutations in lung and colorectal cancers—helping fast-track patients to treatment without extra testing. Identify the origin of cancers when the primary site is unknown, guiding better diagnosis and therapy. Classify breast ER/PR/HER2 status and lung cancer histology subtypes with high precision by interpreting tumor-specific methylation signatures, enhancing standard testing methods. Use pharmacogenomics to identify genetic variations vital for safe and effective use of common anti-cancer therapies, including those with FDA black box labeling. Detect human papillomavirus (HPV) and Epstein-Barr (EBV), which influence prognosis and treatment plans in certain cancers. Determine Homologous Recombination Deficiency (HRD) status to inform use of specific therapies like PARP inhibitors and platinum-based chemotherapy. Use Human Leukocyte Antigen (HLA) genotyping as a biomarker to inform therapy selection and identify clinical trial opportunities. "For the first time ever, we're able to reveal vital details about a tumor – including its fundamental phenotype and biological behavior – from just a blood sample," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "This gives healthcare providers the insights they need about a patient's cancer to make smarter treatment decisions, even when they can't access tumor tissue for analysis. The novel blood-based approach to comprehensive molecular profiling using our Guardant Infinity Smart Liquid Biopsy platform offers immense potential for future applications in cancer and beyond." Comprehensive biomarker testing through immunohistochemistry using tumor tissue has been the standard of care in oncology and helps ensure that clinicians don't miss critical information about a patient's specific type of cancer. The Guardant360 Liquid test now provides access to this extensive molecular profiling information through the blood by looking at the unique methylation signatures of specific tumor biomarkers. Guardant liquid biopsy tests have been clinically validated in more than 1,000 publications and research abstracts. Test results for Guardant360 Liquid are available within seven days. For more information, visit the Guardant Health website. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Michael Weistpress@ +1 317-371-0035 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
27-05-2025
- Business
- Business Wire
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360 ® Liquid test that greatly expand its biomarker identification and cancer subtyping capabilities to help oncologists identify optimal treatment plans. The expanded applications are enabled through the multiomic profiling capabilities of the Guardant Infinity™ smart liquid biopsy platform and its AI learning engine, which analyzes large sets of patient data to identify patterns and refine predictions. Some of the groundbreaking new applications for the Guardant360 Liquid test will allow healthcare providers to do the following in order to improve patient outcomes: Confirm no actionable mutations in lung and colorectal cancers—helping fast-track patients to treatment without extra testing. Identify the origin of cancers when the primary site is unknown, guiding better diagnosis and therapy. Classify breast ER/PR/HER2 status and lung cancer histology subtypes with high precision by interpreting tumor-specific methylation signatures, enhancing standard testing methods. Use pharmacogenomics to identify genetic variations vital for safe and effective use of common anti-cancer therapies, including those with FDA black box labeling. Detect human papillomavirus (HPV) and Epstein-Barr (EBV), which influence prognosis and treatment plans in certain cancers. Determine Homologous Recombination Deficiency (HRD) status to inform use of specific therapies like PARP inhibitors and platinum-based chemotherapy. Use Human Leukocyte Antigen (HLA) genotyping as a biomarker to inform therapy selection and identify clinical trial opportunities. 'For the first time ever, we're able to reveal vital details about a tumor – including its fundamental phenotype and biological behavior – from just a blood sample,' said Helmy Eltoukhy, Guardant Health chairman and co-CEO. 'This gives healthcare providers the insights they need about a patient's cancer to make smarter treatment decisions, even when they can't access tumor tissue for analysis. The novel blood-based approach to comprehensive molecular profiling using our Guardant Infinity Smart Liquid Biopsy platform offers immense potential for future applications in cancer and beyond.' Comprehensive biomarker testing through immunohistochemistry using tumor tissue has been the standard of care in oncology and helps ensure that clinicians don't miss critical information about a patient's specific type of cancer. The Guardant360 Liquid test now provides access to this extensive molecular profiling information through the blood by looking at the unique methylation signatures of specific tumor biomarkers. Guardant liquid biopsy tests have been clinically validated in more than 1,000 publications and research abstracts. Test results for Guardant360 Liquid are available within seven days. For more information, visit the Guardant Health website. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Business Wire
22-05-2025
- Business
- Business Wire
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from more than 19 studies, including a landmark plenary session on the Phase 3 SERENA-6 trial, demonstrating the critical role of Guardant liquid biopsy tests in cancer screening, therapy selection and recurrence monitoring at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago. The data we and our research colleagues are presenting at ASCO demonstrate the clear and growing contribution of liquid biopsy in transforming cancer care and helping to improve patient outcomes. Featured presentations demonstrate the use of Guardant's portfolio of blood tests, real-world data and AI to identify genomic and epigenomic biomarkers that can inform treatment decisions across a variety of solid tumor types. Studies also highlight new capabilities of the Guardant360 Liquid test to identify molecular tumor type in carcinomas of unknown primary and confirm the absence of actionable biomarkers, both enabled by the Guardant Infinity™ smart liquid biopsy platform, Presentation highlights include: Abstract LBA4 plenary session demonstrating the use of the Guardant360® CDx test in detecting emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2- advanced breast cancer in the Phase 3 SERENA-6 trial Abstract 3504 oral session evaluating tissue-free epigenomic-based molecular residual disease (MRD) detection using Guardant Reveal™ in stage III colon cancer patients after surgery and prior to adjuvant therapy. This study showed a robust prognostic utility of Reveal to identify patients with poorer disease-free and overall survival in a large clinical trial cohort of over 2,000 patients with a median follow-up of 6.1 years. Abstract 3584 providing analytic and clinical validation of an algorithm to predict the absence of actionable mutations in ctDNA-negative colorectal and non-small cell lung cancer samples, utilizing genomic and epigenomic profiling with the Guardant360 Liquid test. Abstract 3073 demonstrating application of an epigenomic-based classifier to identify tumor type on liquid biopsy in cancer of unknown primary origin. Study provides validation data for the new molecular tumor type feature of Guardant360 Liquid utilizing DNA methylation signatures across thousands of cancer-specific differentially methylated regions for 14 cancer types. 'The data we and our research colleagues are presenting at ASCO demonstrate the clear and growing contribution of liquid biopsy in transforming cancer care and helping to improve patient outcomes,' said Helmy Eltoukhy, Guardant Health chairman and co-CEO. 'The SERENA-6 study in particular highlights how we are pushing the boundaries of what can be done with liquid biopsy in characterizing disease and potential drug efficacy, providing insights that could potentially change clinical practice.' The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO 2025 can be found on the ASCO website. For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook or visit ASCO booth #25077. Guardant Health and collaborator presentations at ASCO Saturday, May 31, 9:00 am – 12:00 pm CT 3584/253 Analytic and clinical validation of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA Guardant360 Liquid 4200/490 Circulating tumor DNA-based genomic profiling and real-world outcomes in cancer of unknown primary (CUP) Guardant360 Liquid GuardantINFORM Expand Saturday, May 31, 1:30 pm – 4:30 pm CT 8528/8 Genomic and circulating tumor DNA landscape in young-onset non-small cell lung cancer Guardant360 Liquid 8642/122 Use of targeted therapy, healthcare costs, and survival with large panel testing, narrow testing, or no molecular testing in patients with metastatic non-small cell lung cancer (mNSCLC) Guardant360 Liquid Guardant360 CDx 10550/275 Validation of a plasma cell-free DNA methylation-based multi-cancer detection test Shield MCD Expand Sunday, June 1, 2:41 pm – 2:53 pm CT (Plenary Session, Hall B1, Live Stream) LBA4 Oral Clinical Science Symposium: Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial Guardant360 CDx Expand Sunday, June 1, 4:30 pm – 6:00 pm CT (Arie Crown Theater, Live Stream) 1012 Oral Clinical Science Symposium: Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial Guardant OMNI Expand Monday, June 2, 9:00 am – 12:00 pm CT 1052/31 Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab Guardant Reveal 1075/54 Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance Guardant360 Liquid 5052/251 Evaluating the prognostic utility of cell-free (cf)DNA tumor fraction (TF) in metastatic castration-resistant prostate cancer (mCRPC) Guardant360 Liquid 5053/252 Real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) and AR T878A alterations treated with enzalutamide GuardantINFORM 5077/276 Real-world prevalence of homologous recombination repair alterations (HRRa) and poly (ADP-ribose) polymerase inhibitor (PARPi) use/outcomes in patients (pts) with metastatic prostate cancer (mPC) by race and ethnicity GuardantINFORM 5086/285 Association between epigenomic biomarkers and baseline clinical characteristics in patients with mCRPC treated with rucaparib in TRITON2 Guardant Infinity Expand Monday, June 2, 1:30 pm – 4:30 pm CT 3073/388 Application of an epigenomic-based classifier to identify cancer signal of origin on liquid biopsy in cancer of unknown primary cases Guardant360 Liquid 3074/389 HRD status prediction in patients with advanced breast, prostate, ovarian and pancreatic cancers in a liquid biopsy assay Guardant360 Liquid Expand 5512 Oral Abstract Session: Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA Guardant Infinity Expand Online Abstracts e20536 Accelerating treatment decisions with liquid biopsy NGS in non-small cell lung cancer Guardant360 Liquid e13084 Targeted agents for the treatment of hormone receptor–-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+/HER2- MBC) with co-alterations in ESR1 and AKT pathway: A retrospective analysis Guardant360 Liquid Expand About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Associated Press
28-04-2025
- Business
- Associated Press
Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 28, 2025-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Guardant360 ® Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis—including DNA, RNA, AI-powered PD-L1 and exome-wide methylation data—to provide researchers and cancer care teams with a more comprehensive view of cancer. Powered by the Guardant Infinity™ smart liquid biopsy platform, the advanced Guardant360 Tissue test enables insights beyond what can typically be found using tests that do not incorporate comprehensive analysis of epigenetics. These insights can apply to important classes of therapeutics, such as PARP-inhibitors and immunotherapies, as well as important new classes of therapies in late-stage development. The test also enables classification and subtyping of each individual tumor at a much higher resolution, potentially enabling a new era of precision oncology research and clinical applications. In addition, since Guardant360 Tissue is built on the smart liquid biopsy platform, it requires 92% less tissue surface area for analysis than the industry norm. In a real-world assessment, more than 50% of tumor tissue samples from patients failed to meet the surface area requirement – meaning those patients couldn't qualify for testing. 1 The Guardant360 Tissue test allows biopharmaceutical researchers and healthcare providers to successfully analyze tissue samples with 40% fewer slides and thus test more patients using less precious tissue. 'Guardant360 Tissue establishes a new standard in tissue molecular profiling, enabling a much broader dimension of insights to provide biopharma and oncologists with an unprecedented view of each individual tumor,' said Helmy Eltoukhy, Guardant Health chairman and co-CEO. 'And because it is built on our smart liquid biopsy platform, the test will leverage the countless multiomic applications that are being built around our Guardant360 liquid biopsy ecosystem. We believe this synergy will provide a new level of clinical actionability and improved patient outcomes across our entire product portfolio.' For biopharmaceutical partners, the Guardant360 Tissue test offers differentiated molecular profiling by its extensive and unique genomic and epigenomic offering. The test analyzes 742 DNA genes and fusions in 367 RNA genes, with the ability to provide exome-wide analysis of the tumor methylome. Test results are available in less than two weeks. Guardant360 Tissue is covered by Medicare for eligible patients. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. References 1. Tomlins, Scott A et al. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. JCO Precision Oncology. 2021. View source version on CONTACT: Investor Contact: Zarak Khurshid [email protected] Contact: Michael Weist [email protected] +1 317-371-0035 KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Guardant Health, Inc. Copyright Business Wire 2025. PUB: 04/28/2025 08:05 AM/DISC: 04/28/2025 08:04 AM
